Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ultra-short-acting beta-adrenergic blockers.

W H Frishman1, S Murthy, J A Strom

  • 1Albert Einstein College of Medicine, Bronx, New York.

The Medical Clinics of North America
|March 1, 1988
PubMed
Summary

Ultra-short-acting beta-blockers offer rapid, titratable control of adrenergic effects, with quickly reversible actions. Esmolol, a key example, treats arrhythmias and shows promise for perioperative hypertension and myocardial ischemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same author

First Exclusive Reconstruction of the B^{*+}, B^{*0}, and B_{s}^{*0} Mesons and Precise Measurement of Their Masses.

Physical review letters·2026

Area of Science:

  • Pharmacology
  • Cardiology
  • Critical Care Medicine

Background:

  • Parenteral beta-adrenergic blockers are crucial for immediate blockade in critical care.
  • Ultra-short-acting agents offer rapid titration and quick dissipation of effects, enhancing safety.
  • Esmolol is the prototype, with established and potential clinical applications.

Purpose of the Study:

  • To review the characteristics and clinical utility of ultra-short-acting beta-adrenergic blockers.
  • To highlight the role of esmolol in supraventricular tachyarrhythmias.
  • To explore the potential applications of esmolol in perioperative hypertension and acute myocardial ischemia.

Main Methods:

  • Literature review of ultra-short-acting beta-blockers.
  • Analysis of clinical data regarding esmolol efficacy and safety.
  • Pharmacological profile assessment of rapid titration and dissipation.

Main Results:

  • Ultra-short-acting beta-blockers provide precise hemodynamic control.
  • Esmolol demonstrates efficacy in managing supraventricular tachyarrhythmias.
  • Esmolol exhibits potential benefits in perioperative cardiovascular management.

Conclusions:

  • Ultra-short-acting beta-blockers, exemplified by esmolol, are valuable tools in acute cardiovascular care.
  • Rapid reversibility is a key safety feature, allowing for precise therapeutic adjustments.
  • Further investigation into esmolol's role in perioperative settings is warranted.

Related Experiment Videos